BioSpace News Archive

Gestalt Diagnostics and Voicebrook today announced a strategic partnership to benefit information flow and technology interactions in the pathology laboratory.

SPIE, the international society for optics and photonics, and IBM Quantum have selected Wesley Sims, an assistant professor of physics at Morehouse College, as this year’s recipient of the IBM-SPIE HBCU Faculty Accelerator Award in Quantum Optics and Photonics.

Schrödinger, Inc. today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer.

CureVac N.V. today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by coenzyme A (CoA) deficiencies.

NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and six months ended June 30, 2022.

Science 37 Holdings, Inc. and Syapse®, today announced a partnership to deploy proprietary real-world data intelligence and analytics that will help identify suitable patients for oncology clinical trials—ultimately speeding up the enrollment process.

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time Recursion has been ranked by ISS.

89bio, Inc. today announced that it has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of NASH.

Portage Biotech Inc. today announced that Dr. Ian Walters, Chief Executive Officer of Portage, will be appointed Chairman of Portage’s Board of Directors.